Zacks Investment Research cut shares of Mast Therapeutics, Inc. (NASDAQ:SVRA) from a buy rating to a hold rating in a research note released on Friday morning.

According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “

Several other brokerages also recently commented on SVRA. JMP Securities began coverage on Mast Therapeutics in a research note on Monday, September 11th. They issued an outperform rating and a $20.00 target price for the company. Canaccord Genuity restated a buy rating and issued a $18.00 target price on shares of Mast Therapeutics in a research note on Monday, July 17th.

Mast Therapeutics (NASDAQ SVRA) traded down 9.04% during mid-day trading on Friday, reaching $8.55. The company had a trading volume of 547,875 shares. Mast Therapeutics has a one year low of $4.60 and a one year high of $9.88. The company’s market capitalization is $206.94 million. The stock has a 50 day moving average price of $6.04 and a 200 day moving average price of $5.99.

ILLEGAL ACTIVITY WARNING: “Mast Therapeutics, Inc. (SVRA) Downgraded to “Hold” at Zacks Investment Research” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/16/mast-therapeutics-inc-svra-downgraded-to-hold-at-zacks-investment-research.html.

Mast Therapeutics Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Receive News & Stock Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related stocks with our FREE daily email newsletter.